BRCA Gene Mutations And Hereditary Breast And Ovarian Cancer Syndrome From The Perspective Of Ovarian Cancer

Öz

Since ovarian cancer has the highest mortality rates among all the gynecological cancers, there is a tremendous effort to decrease this occasion by surveillance and prophylactic interventions. Ovarian cancer is mostly sporadic, however some people have an increased risk than the overall population due to hereditary and genetic predispositions. BRCA gene mutations are most commonly detected pathology in whom have a hereditary ovarian cancer risk. Genetic counseling, surveillance and prophylactic surgeries with regard to BRCA gene mutations should be applied by an experienced team in a multi-disciplinary approach.

Anahtar Kelimeler

• BRCA,ovarian cancer,screening,follow-up

Over Kanseri Perspektifinde BRCA Gen Mutasyonları Ve Herediter Meme ve Over Kanser Sendromu

Öz

Over kanseri en çok ölümle sonuçlanan jinekolojik kanser olup, tarama çalışmalarıyla beraber önleyici girişimler ile ölüm oranlarının azaltılması için çok fazla çalışma vardır. Hastalık çoğunlukla sporadik gelişse de, ailesel faktörler ve genetik kökenli yatkınlık bazı bireyleri toplumsal oranlara göre artmış bir risk kuşağına sokmaktadır. Ailesel over kanseri yatkınlığı olan kişilerde en sık BRCA gen mutasyonları tespit edilmiş olup, BRCA gen mutasyonu taşıyan kişilere verilecek olan hizmetler; genetik danışmanlık, tarama ve koruyucu girişimler belli bir perspektif içerisinde tecrübeli bir ekip tarafından multi-disipliner bir yapıda yapılmalıdır.

Anahtar Kelimeler

• BRCA,over kanseri,tarama,takip

Kaynakça

1. Committee on Gynecologic Practice SoGO. Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. Obstet Gynecol. 2017;130(3):e146-e9.
2. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433-43.
3. Lancaster JM, Powell CB, Chen LM, Richardson DL, Committee SGO- CP. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015;136(1):3-7.
4. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-61.
5. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ioni- zing radiation. Oncogene. 2003;22(37):5784-91.
6. Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun. 2014;5:3156.
7. David G. Mutch M, Sheri A. Babb, MS, CGC, Philip J. Di Saia, MD. Genes and Cancer: Genetic Counseling and Clinical Management. In: Mutch PJDWTCRSMSMDG, editor. Clinical Gynecologic Oncology. Ninth Editi- on ed: Elsevier; 2018.
8. Karlan BY, Berchuck A, Mutch D. The role of genetic testing for cancer susceptibility in gynecologic practice. Obstet Gynecol. 2007;110(1):155- 67.

9. Committee on Practice Bulletins-Gynecology CoGSoGO. Practice Bul- letin No 182: Hereditary Breast and Ovarian Cancer Syndrome. Obstet Gynecol. 2017;130(3):e110-e26.
10. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritone- al carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032-7.
11. ACOG. Patient Education Fact Sheet, BRCA1 and BRCA2 mutations. 2015.
12. Peters ML, Garber JE, Tung N. Managing hereditary breast can- cer risk in women with and without ovarian cancer. Gynecol Oncol. 2017;146(1):205-14.
13. Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, et al. Contra- lateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(35):5887-92.
14. Pruthi S, Gostout BS, Lindor NM. Identification and Management of Wo- men With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc. 2010;85(12):1111-20.
15. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevan- linna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investiga- tors of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134-47.
16. Vencken PM, Kriege M, Hooning M, Menke-Pluymers MB, Heems- kerk-Gerritsen BA, van Doorn LC, et al. The risk of primary and cont- ralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling. Cancer. 2013;119(5):955-62.
17. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329-33.
18. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117- 30.
19. Andrews L, Mutch DG. Hereditary Ovarian Cancer and Risk Reduction. Best Pract Res Clin Obstet Gynaecol. 2017;41:31-48.
20. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequ- encies of BRCA1 and BRCA2 mutations among 1,342 unselected pa- tients with invasive ovarian cancer. Gynecol Oncol. 2011;121(2):353-7.
21. SGO. SGO Clinical Practice Statement: Genetic Testing for Ovarian Can- cer. October 2014.
22. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68(3):700-10.
23. Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96(1):222-6.
24. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307(4):382- 90.
25. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004;10(7):2473-81.
26. Romero I, Sun CC, Wong KK, Bast RC, Jr., Gershenson DM. Low-grade serous carcinoma: new concepts and emerging therapies. Gynecol On- col. 2013;130(3):660-6.
27. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Austra- lian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-63.
28. Romeo M, Pons F, Barretina P, Radua J. Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor. World J Surg Oncol. 2013;11:13.
29. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002;20(2):463-6.
30. Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, Hooning MJ, et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemo- therapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011;22(6):1346-52.
31. Tan DS, Yap TA, Hutka M, Roxburgh P, Ang J, Banerjee S, et al. Implicati- ons of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel mono- therapy in advanced ovarian cancer. Eur J Cancer. 2013;49(6):1246-53.
32. Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, et al. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet. 2012;205(1-2):34-41.
33. Hartmann LC, Lindor NM. The Role of Risk-Reducing Surgery in Heredi- tary Breast and Ovarian Cancer. N Engl J Med. 2016;374(5):454-68.
34. Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, et al. Distant metastases in ovarian carcinoma. Int J Gynecol Cancer. 2003;13(2):125- 9.
35. Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, et al. Inc- reased incidence of visceral metastases in scottish patients with BR- CA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol. 2010;28(15):2505-11.
36. Sekine M, Yoshihara K, Komata D, Haino K, Nishino K, Tanaka K. Incre- ased incidence of brain metastases in BRCA1-related ovarian cancers. J Obstet Gynaecol Res. 2013;39(1):292-6.
37. Alan C,, Amalina B., Roxburg P., Khan M., Iqbal Y., Rye T. et al. Che- motherapy-induced myelosuppression in ovarian cancer patients with germline BRCA1/2 mutations: A case control study. J Clin Onc 2013.31 (15 suppl)(Abstract 5571).
38. Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer. 2013;109(4):1072- 8.
39. McGlynn P, Lloyd RG. Recombinational repair and restart of damaged replication forks. Nat Rev Mol Cell Biol. 2002;3(11):859-70.
40. Cancer Genome Atlas Research N. Integrated genomic analyses of ova- rian carcinoma. Nature. 2011;474(7353):609-15.
41. Ledermann JA. PARP inhibitors in ovarian cancer. Ann Oncol. 2016;27 Suppl 1:i40-i4.
42. Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther. 2015;8:519-28.
43. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. In- hibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-34.
44. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512-9.
45. Pujade-Lauraine E LJ, Penson RT, et al. Treatment with olaparib mono- therapy in the maintenance setting significantly improves progressionf- ree survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. . Abstract presented at: 2017 Society of Gynecologic Oncologists Annual Meeting; March 14, 2017; National Harbor, MD Abstract LBA2.
46. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154-64.
47. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-Mc- Guinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-51.
48. Conner JR, Meserve E, Pizer E, Garber J, Roh M, Urban N, et al. Out- come of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mu- tations. Gynecol Oncol. 2014;132(2):280-6.
49. Lodder L, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Duiven- voorden HJ, et al. Psychological impact of receiving a BRCA1/BRCA2 test result. Am J Med Genet. 2001;98(1):15-24.
50. van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, van Gool AR, Seynaeve C, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol. 2003;21(20):3867-74.
51. Pieterse AH, van Dulmen AM, Beemer FA, Bensing JM, Ausems MG. Cancer genetic counseling: communication and counselees’ post-visit satisfaction, cognitions, anxiety, and needs fulfillment. J Genet Couns. 2007;16(1):85-96.
52. Biesecker BB, Peters KF. Process studies in genetic counseling: peering into the black box. Am J Med Genet. 2001;106(3):191-8.
53. Kääriäinen H. Recommendations for genetic counselling related to ge- netic testing. http://wwweurogentestorg/fileadmin/templates/eugt/pdf/ guidelines_of_GC_finalpdf.
54. Hall MA, Rich SS. Laws restricting health insurers’ use of gene- tic information: impact on genetic discrimination. Am J Hum Genet. 2000;66(1):293-307.
55. Lammens C, Bleiker E, Aaronson N, Vriends A, Ausems M, Jansweijer M, et al. Attitude towards pre-implantation genetic diagnosis for heredi- tary cancer. Fam Cancer. 2009;8(4):457-64.
56. Kinney AY, Steffen LE, Brumbach BH, Kohlmann W, Du R, Lee JH, et al. Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Gene- tic Counseling Compared With In-Person Counseling: 1-Year Follow-Up. J Clin Oncol. 2016;34(24):2914-24.
57. Schwartz MD, Valdimarsdottir HB, Peshkin BN, Mandelblatt J, Nusbaum R, Huang AT, et al. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol. 2014;32(7):618-26.
58. Percival N, George A, Gyertson J, Hamill M, Fernandes A, Davies E, et al. The integration of BRCA testing into oncology clinics. Br J Nurs. 2016;25(12):690-4.
59. Cohen PA, Nichols CB, Schofield L, Van Der Werf S, Pachter N. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing. Int J Gynecol Cancer. 2016;26(5):892-7.
60. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mefford HC, et al., editors. GeneReviews(R). Seattle (WA)1993.
61. Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer. 2016;69:127-34.
62. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945-56.
63. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Co- lorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295-303.
64. Stirling D, Evans DG, Pichert G, Shenton A, Kirk EN, Rimmer S, et al. Sc- reening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol. 2005;23(24):5588-96.
65. Network. NCC. Genetic/ familial high risk assessment: breast and ovari- an. Version 2.2017. NCCN Clinical Practice Guidelines in Oncology Fort Washington (PA): NCCN; 2016 (Level III).
66. Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Can- cer. 2007;96(9):1335-42.
67. Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict ad- herence to screening schedule. J Clin Oncol. 2013;31(1):49-57.
68. Collaborative Group on Epidemiological Studies of Ovarian C, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contra- ceptives: collaborative reanalysis of data from 45 epidemiological stu- dies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303-14.
69. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010;46(12):2275-84.
70. Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188-98.
71. Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther. 2011;11(8):1197-207.
72. Kuhn E, Kurman RJ, Shih IM. Ovarian Cancer Is an Imported Disease: Fact or Fiction? Curr Obstet Gynecol Rep. 2012;1(1):1-9.
73. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609-15.
74. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction es- timates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80-7.
75. Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol. 2010;116(3):733-43.
76. Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-ab- dominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol. 2005;97(2):457-67.
77. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Sal- pingo-oophorectomy and the risk of ovarian, fallopian tube, and peri- toneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296(2):185-92.
78. Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547-53.
79. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616-22.
80. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006;7(3):223-9.
81. Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, et al. Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017;109(1).
82. Mahe E, Tang S, Deb P, Sur M, Lytwyn A, Daya D. Do deeper sections increase the frequency of detection of serous tubal intraepithelial carci- noma (STIC) in the “sectioning and extensively examining the FIMbriated end” (SEE-FIM) protocol? Int J Gynecol Pathol. 2013;32(4):353-7.
83. Domchek SM, Friebel TM, Garber JE, Isaacs C, Matloff E, Eeles R, et al. Occult ovarian cancers identified at risk-reducing salpingo-oopho- rectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010;124(1):195-203.
84. Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peri- toneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26(25):4160-5.
85. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161-9.
86. Powell CB. Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later. Gynecol Oncol. 2014;132(2):261-3.
87. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014;32(29):3275-83.
88. Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, et al. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol Oncol. 2012;127(1):88-93.
89. Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ. Support of the ‘fallopian tube hypothesis’ in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer. 2013;49(1):132-41.
90. Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer. 2013;23(9):1603-11.
91. Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, et al. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG. 2011;118(7):814-24.
92. Carcangiu ML, Peissel B, Pasini B, Spatti G, Radice P, Manoukian S. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesi- ons: report of 6 cases and review of the literature. Am J Surg Pathol. 2006;30(10):1222-30.
93. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100(1):58-64.
94. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25(10):1283-9.
95. Powell CB, Swisher EM, Cass I, McLennan J, Norquist B, Garcia RL, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with un- suspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol. 2013;129(2):364-71.
96. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, et al. Prophylactic bilateral salpingo-oophorectomy compared with surve- illance in women with BRCA mutations. Obstet Gynecol. 2006;108(3 Pt 1):515-20.
97. Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X, et al. Prop- hylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer. 2007;109(9):1784-90.
98. Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Can- cer. 2004;90(8):1492-7.
99. Manchanda R, Drapkin R, Jacobs I, Menon U. The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in wo- men at increased risk of familial ovarian/tubal cancer. Gynecol Oncol. 2012;124(2):185-91.
100. Meeuwissen PA, Seynaeve C, Brekelmans CT, Meijers-Heijboer HJ, Klijn JG, Burger CW. Outcome of surveillance and prophylactic salpingo-o- ophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol. 2005;97(2):476-82.
101. Deligdisch L, Gil J, Kerner H, Wu HS, Beck D, Gershoni-Baruch R. Ovari- an dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations. Cancer. 1999;86(8):1544-50.
102. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ, 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7(10):821-8.
103. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopau- sal status and early menopause as independent risk factors for cardio- vascular disease: a meta-analysis. Menopause. 2006;13(2):265-79.
104. Elit L, Esplen MJ, Butler K, Narod S. Quality of life and psychosexual ad- justment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer. 2001;1(3-4):149-56.
105. Guidozzi F. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. Cli- macteric. 2016;19(5):419-22.
106. S. M. Domchek TF, S. L. Neuhausen, H. T. Lynch, C. F. Singer, R. A. Eeles, C. Isaacs, N. M. Tung, P. A. Ganz, F. J. Couch, J. N. Weitzel, O. I. Olopade, W. S. Rubinstein, G. E. Tomlinson, G. C. Pichert, M. B. Daly, E. T. Matloff, D. G. Evans, J. E. Garber, T. R. Rebbeck, PROSE Consortium. Is hormone replacement therapy (HRT) following risk-reducing salpin- go-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? J Clin Oncol 29: 2011 (suppl; abstr 1501). 2011.